无锡途深智合人工智能科技有限公司及子公司上海途深生物科技有限责任公司（以下简称「途深智合」）近日宣布，成功完成数百万元的天使轮融资。此次融资由诚美资本独家投资，资金将主要用于实验室建设与团队扩张。
途深智合成立于2023年，专注于人工智能蛋白质设计和制造，致力于为合成生物领域开发创新解决方案和新产品。该公司利用尖端的人工智能技术，加速蛋白质工程的研究与应用，推动生物科技的创新发展。
随着生物技术的发展，合成生物学已经成为全球科研和产业界关注的热点。途深智合凭借其核心技术，有望在合成生物学市场中占据一席之地，为医疗、农业、工业等多个领域带来革命性的变化。
此次天使轮融资，不仅为途深智合的发展注入了强劲动力，也为合成生物学领域的研究与应用提供了新的可能性。诚美资本的投资，显示了资本市场对途深智合技术实力和市场潜力的认可。
随着实验室的建成和团队的完善，途深智合将进一步加强技术研发和产品创新，以期在未来的市场竞争中取得更大的优势。
英文标题：TuShenChe Biotech Secures Angel Investment for AI-driven Protein Design
英文关键词：Angel Funding, AI Protein Design, Synthetic Biology
英文新闻内容：
TuShenChe Biotech, an AI-driven protein design and manufacturing company based in Wuxi and Shanghai, has recently announced the completion of several million RMB in angel funding. The investment was led by Chengmei Capital and will be used to build a laboratory and expand the team.
Established in 2023, TuShenChe Biotech is dedicated to developing innovative solutions and products for the field of synthetic biology through artificial intelligence. The company accelerates research and applications in protein engineering, driving the innovative development of biotechnology.
As the field of synthetic biology continues to grow, TuShenChe Biotech is poised to make significant contributions to various industries, including healthcare, agriculture, and manufacturing, with its cutting-edge technology.
The angel investment not only provides a strong impetus for TuShenChe Biotech’s development but also opens up new possibilities for research and applications in the synthetic biology field. Chengmei Capital’s investment reflects the capital market’s recognition of TuShenChe Biotech’s technical capabilities and market potential.
With the completion of the laboratory and the expansion of the team, TuShenChe Biotech is expected to further strengthen its research and product innovation, aiming to gain a significant advantage in the competitive market.
【来源】https://36kr.com/p/2686282258132355
Views: 3